Calidi Biotherapeutics, Inc. (CLDI)
CLDI moved a median of -1.05% 30 minutes after news, and -1.91% by the close. How CLDI actually reacts to news — the realized, point-in-time move the market made, measured across 329 labeled events over the last three years with zero look-ahead.
CLDI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 325 |
| 30-min | -1.05% | 36% | 327 |
| 60-min | -1.51% | 31% | 329 |
| to close | -1.91% | 31% | 328 |
| Middle 50% of CLDI reactions | -3.77% to +1.35% |
|---|---|
| Median reaction (30-min) | -1.05% |
| Measured reactions | 329 |
Half of all Calidi Biotherapeutics, Inc. news events land between -3.77% and +1.35% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CLDI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CLDI's baseline. Nothing else.
Recent CLDI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency | Press release | GlobeNewswire | +0.01% | -2.73% | |
| Form 8-K Calidi Biotherapeutics, For: Sep 21 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | -2.73% | |
| Form 8-K Calidi Biotherapeutics, For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | +1.82% | -0.91% | |
| Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering | Press release | GlobeNewswire | +1.30% | +10.44% | |
| Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +0.00% | -2.17% | |
| Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | +2.50% | +6.00% | |
| Form 10-Q Calidi Biotherapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.50% | +6.00% | |
| Form 8-K Calidi Biotherapeutics, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +2.50% | +6.00% | |
| Form 8-K Calidi Biotherapeutics, For: Jul 27 | SEC filing · Form 8-K | SEC EDGAR | -1.85% | +3.70% | |
| Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference | Press release | GlobeNewswire | -0.55% | +9.28% | |
| Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers | Press release | GlobeNewswire | +0.95% | -0.50% | |
| Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 | Press release | GlobeNewswire | +0.95% | -0.50% | |
| Form 8-K Calidi Biotherapeutics, For: Jul 10 | SEC filing · Form 8-K | SEC EDGAR | -1.12% | +2.50% | |
| Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 | Press release | GlobeNewswire | +1.19% | +4.54% | |
| Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit | Press release | GlobeNewswire | -1.61% | +0.96% | |
| Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors | Press release | GlobeNewswire | -0.70% | -0.13% | |
| Form 8-K Calidi Biotherapeutics, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -0.70% | -0.13% | |
| Form 8-K Calidi Biotherapeutics, For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | +0.06% | -1.24% | |
| Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study | Press release | GlobeNewswire | -1.70% | -0.13% | |
| Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026 | Press release | GlobeNewswire | -4.68% | +2.34% | |
| Form DEFA14A Calidi Biotherapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -4.68% | +2.34% | |
| Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9 | Press release | ACCESS Newswire | -0.18% | +4.32% | |
| Form 8-K Calidi Biotherapeutics, For: May 28 | SEC filing · Form 8-K | SEC EDGAR | -3.76% | -1.34% | |
| Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting | Press release | GlobeNewswire | -7.66% | -3.75% | |
| Calidi Biotherapeutics Provides Required NYSE American Disclosure | Press release | GlobeNewswire | -7.66% | -3.75% | |
| Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights | Press release | GlobeNewswire | +3.56% | +16.00% | |
| Form 10-Q Calidi Biotherapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.56% | +16.00% | |
| Form 8-K Calidi Biotherapeutics, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +3.56% | +16.00% | |
| Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston | Press release | GlobeNewswire | -1.44% | +6.78% | |
| Form 8-K Calidi Biotherapeutics, For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -3.50% | -3.64% | |
| Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI | Press release | GlobeNewswire | -6.21% | -0.67% | |
| Form DEF 14A Calidi Biotherapeutics, For: Apr 29 | SEC filing · Form DEF | SEC EDGAR | -1.28% | +12.16% | |
| Form DEFA14A Calidi Biotherapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -1.28% | +12.16% | |
| Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 | Press release | GlobeNewswire | +0.65% | -10.31% | |
| Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 | Press release | GlobeNewswire | -3.67% | -7.33% | |
| Form PRE 14A Calidi Biotherapeutics, For: Apr 17 | SEC filing · Form PRE | SEC EDGAR | -3.67% | -7.33% | |
| Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms | Press release | GlobeNewswire | -1.54% | -0.52% | |
| Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy | Press release | GlobeNewswire | -0.83% | -4.41% | |
| Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy | Press release | GlobeNewswire | +0.71% | +1.09% | |
| Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 | Press release | GlobeNewswire | -1.32% | -2.96% | |
| Form 8-K Calidi Biotherapeutics, For: Mar 29 | SEC filing · Form 8-K | SEC EDGAR | -4.13% | +2.04% | |
| Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 | Press release | GlobeNewswire | -1.96% | +1.08% | |
| Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights | Press release | GlobeNewswire | -4.74% | -16.11% | |
| Form 10-K Calidi Biotherapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.74% | -16.11% | |
| Form 8-K Calidi Biotherapeutics, For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | -4.74% | -16.11% | |
| Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials | Press release | GlobeNewswire | -0.19% | -5.51% | |
| Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing | Press release | GlobeNewswire | +1.48% | -2.91% | |
| Form 8-K Calidi Biotherapeutics, For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | +1.48% | -2.91% | |
| Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option | Press release | GlobeNewswire | +0.74% | +2.86% | |
| Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering | Press release | GlobeNewswire | -2.83% | -5.30% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CLDI section they belong to.
Where else CLDI is measured.
CLDI earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Calidi Biotherapeutics, Inc.'s median reaction calculated?
Every labeled CLDI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 329 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 36% of CLDI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CLDI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.